Advaxis Inc. (NASDAQ:ADXS) dropped 4.3% during mid-day trading on Tuesday . The stock traded as low as $14.12 and last traded at $14.18, with a volume of 1,184,992 shares. The stock had previously closed at $14.81.

ADXS has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and set a $23.00 price target on shares of Advaxis in a research note on Friday, August 5th. Jefferies Group restated a “buy” rating on shares of Advaxis in a research note on Friday, June 10th. FBR & Co restated an “outperform” rating and set a $34.00 price target on shares of Advaxis in a research note on Thursday, July 7th. Finally, Barclays PLC raised their price target on shares of Advaxis from $15.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 3rd. Six research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus target price of $25.80.

The firm’s market capitalization is $467.11 million. The firm’s 50-day moving average price is $10.20 and its 200-day moving average price is $8.58.

In other news, Director David Sidransky sold 22,808 shares of the company’s stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $15.01, for a total value of $342,348.08. Following the transaction, the director now owns 91,759 shares in the company, valued at $1,377,302.59. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Richard J. Berman sold 18,000 shares of the company’s stock in a transaction that occurred on Monday, August 8th. The stock was sold at an average price of $15.21, for a total transaction of $273,780.00. Following the completion of the transaction, the director now owns 66,430 shares in the company, valued at approximately $1,010,400.30. The disclosure for this sale can be found here.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.